SUMMARY Dopaminergic mechanisms may be involved in the regulation of aldosterone secretion in humans and in the rat. Whether these effects are indirect or are exerted directly at the adrenal level has not yet been resolved. We now report the identification of dopaminergic binding sites in the bovine adrenal zone glomerulosa using pHJspiperone, a butyrophenone with high affinity for D 2 dopamine receptors. Specific [ 3 H]spiperone binding (defined as binding displaceable by 10 /xm (+ )-butaclamol) reached equilibrium within 20 minutes at 22°C, was reversible, and was heat labile (60°C). Binding was of high affinity and saturable with a K A of 1.8 ± 0.2 nM and maximal specific binding of 38 ± 8 fmol/mg (means ± SEM; n = 18). and rats 45 in vivo. This effect is independent of changes in established regulators of mineralocorticoid secretion, such as the renin-angiotensin axis, serum potassium, and adrenocorticotropic hormone (ACTH).
M
ETOCLOPRAMIDE, a dopaminergic antagonist, has been shown to selectively stimulate the secretion of aldosterone and 18-hydroxycorticosterone in humans, 12 monkeys, 3 and rats 45 in vivo. This effect is independent of changes in established regulators of mineralocorticoid secretion, such as the renin-angiotensin axis, serum potassium, and adrenocorticotropic hormone (ACTH). 6 " 10 The metoclopramide-induced increase in plasma aldosterone is preserved in hypophysectomized or anephric patients 1 -6 and in hypophysectomized rats. 7 Further, the aldosterone response to metoclopramide can be blocked by infusion of dopamine"' l2 but not by dexamethasone, 8 saralasin, or converting enzyme inhibitors, 9 -10 which suggests that a specific dopaminergic mechanism is involved. Disagreement exists as to whether dopamine and metoclopramide directly affect the secretion of aldosterone at the adre-nal level. Evidence that these agents modulate aldosterone output by isolated glomerulosa cells in vitro has been equivocal. 5 -13~18 In sheep, both the ganglionic blocker trimetaphan 19 and dexamethasone 20 have been observed to block the aldosterone response to metoclopramide, which suggests that ACTH-mediated or neurogenic pathways (or both) could also be involved in the release of aldosterone, at least under certain circumstances. A similar dexamethasone-induced attenuation of the aldosterone response to higher doses of metoclopramide has been also demonstrated in humans. 21 If dopamine inhibits the secretion of aldosterone at the adrenal level, its action might be exerted through local dopaminergic receptors. Preliminary evidence suggests that rat 22 and calf 23 adrenal zona glomerulosa (AZG) contain dopamine binding sites. This study attempted to demonstrate the existence of dopaminergic receptors in membranes from bovine AZG cells.
Materials and Methods
Fresh bovine adrenals were obtained from a local slaughterhouse. The subcapsular layer (outer 0.5 mm) of the bovine adrenals from two to five different animals in each experiment was collected and minced with scissors. Fragments were immediately placed in204 HYPERTENSION VOL 8, No 3, MARCH 1986 pargyline and homogenized in a Teflon glass homogenizer by seven strokes (1000 rpm). The homogenate was centrifuged for 10 minutes at 750 g at 4°C. The supernatant was collected and centrifuged for 30 minutes at 45,000 g. The resultant pellet was resuspended in the homogenization buffer and recentrifuged at 45,000 g for 30 minutes (4°C). Membranes were then resuspended in the same buffer solution (pH 7.4 at 22 °C) to yield final protein concentrations of approximately 1.5 to 5 mg/ml.
Membranes ] spiperone was separated from free spiperone by rapid filtration through GF/C glass fiber filters (Whatman, Clifton, NJ, USA) and was followed by two washes with 5 ml of ice-cold Tris buffer solution. The total filtration time (under pressure of -15 atm) was less than 10 seconds. Filters were air dried and subsequently vigorously shaken for 30 minutes in a BetaMax (WestChem, San Diego, CA, USA), scintillation fluid. After equilibration for 2 hours at room temperature, samples were counted in a Beckman beta-counter (Palo Alto, CA, USA) with a counting efficiency of 45%. Specific binding, the difference of [ 3 H]spiperone binding in the absence and presence of 10 fiM ( + )-butaclamol, was 75 to 85% when the radioligand concentration was in the range of the dissociation constant (K A , 1-3 nM).
The sources for the different agents used in the binding assays were as follows: dopamine hydrochloride from Astra Pharmaceutical Products, Worcester, MA, USA; ( -)-epinephrine, ( -)-norepinephrine, serotonin, angiotensin II (ANG II; 1-aspartic, 5 isoleucine), dithiotreitol, and leupeptin from Sigma Chemical, St To determine cyclic adenosine 3',5'-monophosphate (cyclic AMP) generation, membranes were prepared as already described, but all steps were performed using a buffer solution containing 50 mM Hepes (pH 7. 
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The AZG cells were prepared from the same tissue fragments used for the binding studies (i.e., the outer subcapsular 0.5 mm of the cortex) using a method adopted from Williams and colleagues 23 ' 26 for bovine AZG. In brief, tissue was first minced with scissors. Fragments in aliquots of 2.5-g wet weight were preincubated for 50 minutes at 37°C in 12.5 ml of a modified Krebs-Ringer bicarbonate solution with collagenase, 1.85 mg/ml, and DNAse, 0.025 mg/ml. The solution also contained 4% bovine serum albumin; glucose, 2 mg/ml; L-glutamine, 0.2 mg/ml; 1.25% (vol/ vol) essential amino acids; and 1.25% (vol/vol) nonessential amino acids. The potassium concentration was 3.7 mmol/L. Dopamine hydrochloride in 0.1% ascorbic acid also was added to the preincubation phase to yield a final concentration of 10" 4 M. At the end of the preincubation phase, the resultant cell dispersion was filtered once through a stainless steel gauze and then washed twice in the Krebs-Ringer buffer solution at room temperature. Cells were then resuspended in the Krebs-Ringer buffer solution to yield 50,000 to 200,000 cells/ml. Dopamine, 50 fi\, in 0.1% ascorbic acid or ANG II, or both, was then added to 1.95 ml of the cell suspension. Immediately after 60-minute incubation of triplicate or quadruplicate samples at 37°C, the incubates were frozen and aldosterone (in the total incubate volume) was assayed as previously described. 27 Results are expressed as means ± SEM. [ 3 H]Spiperone binding data were assessed by using LIGAND, a weighted, nonlinear, least-squares analysis program. 28 -N Comparisons between K d and maximal specific binding capacity obtained under different conditions were made by the Student's t test or analysis of variance as necessary.
Results

Binding Studies
Specific binding of Preincubation of the membrane preparation at 60 °C for 10 minutes resulted in complete loss of binding sites. Binding also displayed marked temperature dependence ( Figure 4 ). When incubation temperature was 4°C rather than 22°C, specific [ 3 H]spiperone binding increased" by about twofold and remained stable longer; approximately 90% of the maximal binding was still detectable after 120 minutes. At 37°C, maximal specific binding was only about half of that observed at 22°C (see Figure 4) . In some experiments, the standard procedure at 22°C was preceded by preincubation of the membrane preparation for 10 minutes at 22°C, with and without various agents. After two washes at 4°C, incubation for 30 minutes was performed as already described. Preincubation of membranes with dopamine (10~2 or 10~3 M) increased subsequent [ 3 H]spiperone binding by 115 ± 25% (n = 4) and raised the binding at 22°C to the range observed at 4°C. Conversely, preincubation or coincubation (i.e., adding agents to the incubation medium) with dithiotreitol (10~3 M), a sulfhydryl reducing agent, or leupeptin (0. fraction was 50 ± 10% (n = 3) of the total binding site population, whereas domperidone displayed high affinity for only 12 ± 5% (n = 5) of the binding sites. Serotonin, epinephrine, and norepinephrine had no effect on [ 3 H]spiperone binding even with the highest concentrations used (lO" 4 M). In several experiments, ACTH (2.5 x 10" 8 M), ANGII(2.5 x 10-9 to2.5 x 10" 8 M), or potassium (8 mM KC1) was added to the incubation medium and binding studies were repeated in the same membrane preparations with and without these agents. The resulting dissociation constants were 2.2 ± 0.5 (n = 5), 2.3 ± 0.6 (n = 4), 2.5 ± .04 {n = 3), and 2.4 ± 0.5 nM (n = 3) for control, ANG II, ACTH, and KC1 containing preparations, respectively. The maximal binding capacity was also unaffected by coincubation with these agents (maximal specific binding capacity of 43 ± 10, 48 ± 8, 40 ± 10, and 50 ± 13 fmol/mg for control, ANG II, ACTH, and KC1 containing preparations, respectively).
Cyclic AMP Studies
Although 25 /xH ACTH increased cyclic AMP production by AZG membranes from 74.6 ± 1.4 to 103.9 ± 3.5 pmol/mg/5 min (p < 0.01), 10^ M dopamine had no effect on basal (73.2 ± 1.2 pmol/mg/5 min) or ACTH-stimulated (104.9 ± 5.4 pmol/mg/5 min) cyclic AMP generation.
Basal aldosterone production (368 ± 40 pg/10 5 cells) increased to 764 ± 56 pg/10 3 cells in the presence of 2.5 x KHM ANG II (p < 0.01). Dopamine (10" 4 M) had no effect on basal aldosterone production but attenuated the response of AZG cells to ANG II (489 ± 31 pg/10 5 cells; p < 0.01 compared with values for ANG 11). At concentrations lower than 10~3 M dopamine had no effect on aldosterone output ( Figure 7) .
H]spiperone (S) binding to adrenal zona glomerulosa membranes. [ 3 H]Spiperone (2 nM) was added to the membrane preparation at each temperature in the presence and absence of 10 fiM (+ )-butaclamol. Points represent the mean of three similar experiments (fin = fmol).
FIGURE 5. Inhibition of binding of 2.5 nM [ 3 H]spiperone to bovine adrenal zona glomerulosa membranes by the agonists LY 171555, SKF 38393, dopamine, serotonin, (-)-epinephrine, and (-)-norepinephrine. For each agent, three to five experiments at se\>en different concentrations were run.
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Discussion
Our results demonstrate the existence of specific, saturable, and high affinity binding sites for [ 3 H]spiperone in the subcapsular layer of the bovine adrenal. Current classification of dopaminergic receptors includes D, dopamine receptors, defined by their association to adenylate cyclase activation, and D 2 receptors, which do not activate this enzyme. 30 Butyrophenones and ergot derivatives have high affinity for D 2 -receptors, whereas thioxanthenes display high affinity for D,-receptors. Dopamine itself exhibits low affinity for D,-receptors, low affinity for some D 2 -receptors such as those in the pituitary gland, 31 and a uniformly high affinity only for the more recently defined D 3 -receptors. 32 ' 33 In this study, dopamine exhibited low affinity for the AZG binding sites as previously described for some pituitary and caudate nucleus membranes. The protective effect of preincubation with dopamine on subsequent [
3 H]spiperone binding at 22°C is of interest and might imply that the observed temperature dependence results from binding site rather than ligand degradation. Although the mechanisms underlying the protective effect of dopamine in our assay remain to be elucidated, it is noteworthy that preincubation with dopamine has been previously shown to exert a similar protective effect under different conditions. Preincubation with dopamine resulted in an increase in [ 3 H]dopamine binding to D 2 -receptor sites, presumably through clearing of endogenous guanine nucleotides from the guanine nucleotide regulatory factor. 40 However, dopamine antagonist binding, with a single reported exception, 41 is not affected by guanine nucleotides, 42 ' 43 which renders this mechanism an unlikely explanation for the protection exerted by dopamine in our assay in which [ 3 H]spiperone, a D 2 -antagonist, was used. With regard to dopamine antagonist binding, preincubation with either dopamine or domperidone inhibited inactivation of [ 3 H]spiperone binding by sulfhydryl alkylating agents, which suggests that receptor occupancy of either agonists or antagonists provides protection against receptor degradation by these agents. 43 The failure of dithiotreitol, a sulfhydryl reducing agent, to diminish the observed temperature dependence suggests that decreased binding at higher temperatures does not result from the formation of disulfide bonds. On the other hand, that preincubation with dithiotreitol did not hinder subsequent binding is in agreement with previous observations with pituitary D 2 -receptors. 43 This finding differs, however, from that in /3-adrenergic receptors, in which dithiotreitol inhibited ligand binding, presumably by reducing an essential disulfide bond. 44 Finally, the possibility that the temperature dependence of our binding assay is related to tissue contained proteolytic activity, such as impairs the stability of some steroid and acetylcholine receptors, 45 was tested by the addition of leupeptin, a protease inhibitor, to the assay medium. Although no protective effect of leupeptin on [ 3 H]spiperone binding was shown, there were other protease inhibitors that might have provided such protection.
The inference that the AZG [ 3 H]spiperone binding site population is pertinent to the dopaminergic inhibition of aldosterone biosynthesis and secretion suffers from the lack of current information regarding the effects of in vivo of dopamine on bovine aldosterone output. Nevertheless, preliminary observations indicate that the binding affinities of the AZG dopamine binding sites are similar in bovine, rat, and human tissues, 46 thus suggesting that the easily accessible and relatively abundant bovine adrenal may serve as a useful model for the study of the AZG dopamine receptors. Further, while the effects of dopaminergic agonists and antagonists in living cattle have not been defined, two groups of investigators have demonstrated that dopamine modulates aldosterone output by bovine AZG cells in vitro. 13 - 47 In general, not only is the effective dopamine concentration determined in these studies similar to that found in the present AZG cell experiments, but the doses needed to elicit significant inhibition of aldosterone response are also in agreement with the dopamine concentration required to significantly affect AZG [ 3 H]spiperone binding. McKenna et al. 13 reported that Kt 1 to 10" 5 M dopamine induced 25 to 45% inhibition of ANG II-stimulated aldosterone biosynthesis in collagenase dispersed bovine AZG cells. DeLean et al. 4 * failed to show any effect of dopamine on aldosterone in isolated AZG cells in primary culture (72 hours). When AZG cells were coincubated with adrenomedullary cells, however, both dopamine and dopamine-3-sulfate (but not dopamine-4-sulfate) inhibited ANG II-stimulated aldosterone secretion by 50% in a dose-dependent manner (lO^-lO" 4 M), 4 * which suggests that continuous availability of dopamine is critical for the preservation of AZG responsiveness to this hormone. Of relevance in this regard are the observations that high concentrations of dopamine are found in the adrenal cortex.
4749 -"
The observation that high concentrations of dopamine (>]()-* M) are required to demonstrate an inhibitory effect on aldosterone secretion by AZG cells in vitro has led investigators to question the specificity of this inhibition. 7 The present study suggests that this information should be interpreted in light of the observed low affinity of dopamine to some D 2 -receptors in conjunction with the reported high concentrations of dopamine available in the adrenal cortex. Although our results do not conclusively establish the link between the AZG dopaminergic binding sites and dopaminergic inhibition of aldosterone in bovine AZG cells, they nevertheless underscore the need to document preservation of dopaminergic binding sites whenever a dopaminergic effect cannot be shown in AZG cell systems in vitro. 
